Cite
Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
MLA
Chen, Xinyi, et al. “Co-Mutation of TP53 and PIK3CA in Residual Disease after Neoadjuvant Chemotherapy Is Associated with Poor Survival in Breast Cancer.” Journal of Cancer Research & Clinical Oncology, vol. 145, no. 5, May 2019, pp. 1235–42. EBSCOhost, https://doi.org/10.1007/s00432-019-02873-8.
APA
Chen, X., Guo, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., Xu, Y., & Xie, Y. (2019). Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer. Journal of Cancer Research & Clinical Oncology, 145(5), 1235–1242. https://doi.org/10.1007/s00432-019-02873-8
Chicago
Chen, Xinyi, Yonghai Guo, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Ye Xu, and Yuntao Xie. 2019. “Co-Mutation of TP53 and PIK3CA in Residual Disease after Neoadjuvant Chemotherapy Is Associated with Poor Survival in Breast Cancer.” Journal of Cancer Research & Clinical Oncology 145 (5): 1235–42. doi:10.1007/s00432-019-02873-8.